



**NOVA PHARMA SOLUTIONS BERHAD**  
Registration No. 197701003731 (34608-K)  
(Incorporated in Malaysia)

**FINANCIAL STATEMENTS FOR THE  
HALF YEAR ENDED 30 JUNE 2025**

**CHARACTERISTICS OF THE LEAP MARKET OF BURSA MALAYSIA SECURITIES  
BERHAD (“BURSA SECURITIES”)**

THE LEAP MARKET HAS BEEN POSITIONED AS A MARKET DESIGNED TO ACCOMMODATE CORPORATIONS TO WHICH A HIGHER INVESTMENT RISK MAY BE ATTACHED THAN OTHER CORPORATIONS LISTED ON THE ACE MARKET OR MAIN MARKET OF BURSA SECURITIES. IT IS A QUALIFIED MARKET WHICH IS MEANT MAINLY FOR SOPHISTICATED INVESTORS ONLY. ONLY EXISTING SECURITIES HOLDERS AND SOPHISTICATED INVESTORS ARE ALLOWED TO PARTICIPATE IN CORPORATE EXERCISES UNDERTAKEN BY NOVA PHARMA SOLUTIONS BERHAD (“NPS” OR THE “COMPANY”). SOPHISTICATED INVESTORS SHOULD BE AWARE OF THE POTENTIAL RISKS OF INVESTING IN SUCH CORPORATIONS AND SHOULD MAKE THE DECISION TO INVEST ONLY AFTER DUE AND CAREFUL CONSIDERATION.

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 30 JUNE 2025**

	UNAUDITED INDIVIDUAL		UNAUDITED CUMULATIVE	
	6 months ended		6 months ended	
	30 June	30 June	30 June	30 June
	2025 RM'000	2024 RM'000	2025 RM'000	2024 RM'000
Revenue	7,357	5,119	7,357	5,119
Cost of sales	(2,037)	(1,683)	(2,037)	(1,683)
Gross profit	5,320	3,436	5,320	3,436
Other operating income	216	57	216	57
Operating expenses	(1,806)	(1,100)	(1,806)	(1,100)
Profit from operating activities	3,730	2,393	3,730	2,393
Finance costs	-	-	-	-
<b>Profit before tax</b>	<b>3,730</b>	<b>2,393</b>	<b>3,730</b>	<b>2,393</b>
Tax expenses	(761)	(469)	(761)	(469)
<b>Profit for the financial year</b>	<b>2,969</b>	<b>1,924</b>	<b>2,969</b>	<b>1,924</b>
Other comprehensive income, net of tax	-	-	-	-
<b>Total comprehensive income for the financial year</b>	<b>2,969</b>	<b>1,924</b>	<b>2,969</b>	<b>1,924</b>
 <b>Profit for the financial year attributable to:</b>				
Owners of the Company	2,969	1,924	2,969	1,924
Non-controlling interest	-	-	-	-
	<b>2,969</b>	<b>1,924</b>	<b>2,969</b>	<b>1,924</b>
 <b>Total comprehensive income for the financial year attributable to:</b>				
Owners of the Company	2,969	1,924	2,969	1,924
Non-controlling interest	-	-	-	-
	<b>2,969</b>	<b>1,924</b>	<b>2,969</b>	<b>1,924</b>
 <b>EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY</b>				
Basic (Sen)	1.99	1.29	1.99	1.29
Diluted (Sen)	N/A	N/A	N/A	N/A

**Note:**

*The basis of preparation of the Unaudited Condensed Statement of Profit or Loss and Other Comprehensive Income are detailed in Note A1 and the accompanying explanatory notes attached to this interim financial report.*

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 30 JUNE 2025**

	Unaudited as at 30.06.25 RM'000	Audited as at 31.12.2024 RM'000
<b>NON-CURRENT ASSETS</b>		
Right-of-use Asset	10	38
Property, plant and equipment	296	175
	<b>306</b>	<b>213</b>
<b>CURRENT ASSETS</b>		
Trade receivables	13,022	169
Other receivables, deposits and prepayments	339	329
Contract assets	9,097	4,287
Current tax assets	847	368
Short-term funds	10,264	3,426
Fixed Deposit with licensed bank	11,149	12,582
Cash and bank balances	138	683
	<b>44,856</b>	<b>21,844</b>
<b>TOTAL ASSETS</b>	<b>45,162</b>	<b>22,057</b>
<b>EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY</b>		
Share capital	7,985	7,985
Retained earnings	13,430	10,461
	<b>21,415</b>	<b>18,446</b>
<b>CURRENT LIABILITIES</b>		
Trade payables	704	265
Other payables and accruals	1,523	1,962
Lease liabilities	-	41
Provision for Taxation	-	392
Contract liabilities	21,500	941
	<b>23,727</b>	<b>3,601</b>
<b>NON-CURRENT LIABILITIES</b>		
Lease liabilities	10	-
Deferred Tax liabilities	10	10
<b>TOTAL LIABILITIES</b>	<b>23,747</b>	<b>3,611</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>45,162</b>	<b>22,057</b>
<b>NET ASSETS PER SHARE (RM)<sup>(1)</sup></b>	<b>0.144</b>	<b>0.124</b>

**Notes:**

*The basis of preparation of the Unaudited Condensed Statement of Financial Position are detailed in Note A1 and the accompanying explanatory notes attached to this interim financial report.*

*(1) Net assets per share is calculated based on the Company's number of ordinary shares at the end of the reporting period.*

**UNAUDITED CONDENSED STATEMENTS OF CHANGES IN EQUITY  
FOR THE HALF-YEAR ENDED 30 JUNE 2025**

	Share Capital RM'000	Retained Earnings RM'000	Total Equity RM'000
<b>Opening balance on 1 January 2025</b>	<b>7,985</b>	<b>10,461</b>	<b>18,446</b>
Total comprehensive profit for the period	-	2,969	2,969
<b>Closing balance on 30 June 2025</b>	<b>7,985</b>	<b>13,430</b>	<b>21,415</b>

  

Opening balance on 1 January 2024	7,985	6,626	14,611
Total comprehensive profit for the period	-	3,835	3,835
Closing balance on 31 December 2024	7,985	10,461	18,446

**Note:**

*The basis of preparation of the Unaudited Condensed Statement of Changes in Equity are detailed in Note A1 and the accompanying explanatory notes attached to this interim financial report.*

**UNAUDITED CONDENSED STATEMENT OF CASH FLOWS  
FOR THE HALF-YEAR ENDED 30 JUNE 2025**

	Unaudited 6 months ended 30 June	
	2025	2024
	RM'000	RM'000
<b>Operating activities</b>		
Profit before tax	3,730	2,394
Adjustments for:		
Depreciation of plant and equipment	60	34
Depreciation of right-of use assets	29	29
Fair value gain on short term funds	(79)	(115)
Dividend Income	(10)	(40)
Unrealized gain on foreign exchange	(92)	(90)
Unrealized loss on foreign exchange	549	103
Interest Income	(182)	(8)
Interest expenses	30	3
<b>Operating profit before working capital changes</b>	<b>4,035</b>	<b>2,310</b>
Change in trade and other receivables	12,929	905
Change in other deposit and prepayment	10	91
Change in contract assets	4,883	343
Change in contract liabilities	-	(157)
Change in other payables and accruals	345	(274)
Change in trade payables	716	(32)
<b>Cash generated from operations</b>	<b>22,918</b>	<b>3,186</b>
Tax paid	(454)	(356)
Interest expenses	(30)	(3)
<b>Net cash generated from operating activities</b>	<b>22,434</b>	<b>2,827</b>
<b>Investing activities</b>		
Dividends Income	10	40
Interest Income	182	8
Fair value gain on short term funds	79	115
Purchase of property, plant and equipment	181	-
<b>Cash generated in investing activities</b>	<b>452</b>	<b>163</b>
<b>Financing activities</b>		
Repayment of lease liabilities	(31)	(29)
Pledged of fixed deposit / Interest Income	(11,149)	(7,299)
<b>Net cash generated from investing activities</b>	<b>(11,180)</b>	<b>(7,328)</b>
<b>Net increase in cash and cash equivalents</b>	<b>11,706</b>	<b>(4,338)</b>
Effect of foreign exchange rate changes	(5,413)	(13)
Cash and cash equivalents at beginning of financial year	4,109	13,521
<b>Cash and cash equivalents at the end of financial year</b>	<b>10,402</b>	<b>9,170</b>

	<b>Unaudited</b> <b>6 months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RM'000</b>	<b>RM'000</b>
<b><u>Analysis of cash and cash equivalent: -</u></b>		
Short Term Fund	10,264	8,977
Cash and bank balances	138	193
<b>Cash and cash equivalents at the end of financial year</b>	<b>10,402</b>	<b>9,170</b>

**Note:**

*The basis of preparation of the Unaudited Condensed Statement of Cash Flows are detailed in Note A1 and the accompanying explanatory notes to this interim financial report.*

**A EXPLANATORY NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR  
ENDED 30 JUNE 2025**

**A1 COMPLIANCE WITH FINANCIAL REPORTING STANDARD AND LEAP MARKET LISTING  
REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

**Basis of Preparation**

The financial statements of the Group and the Company have been prepared in accordance with Malaysian Financial Reporting Standards (“MFRSs”), International Financial Reporting Standards (“IFRSs”) and the requirements of the Companies Act 2016 in Malaysia.

The Group and the Company have applied to the following accounting standards and amendments of the MFRSs for the financial year beginning on 1 January 2024 : -

**Amendments to MFRSs**

MFRS 7 Financial Instruments: Disclosures – Supplier Finance Arrangements

MFRS 16 Leases – Lease Liability in a Sale and Leaseback

MFRS 101 Presentation of Financial Statements – Non-current Liabilities with Covenants

MFRS 101 Presentation of Financial Statements – Classification of Liabilities as Current or Non-  
Current

MFRS 107 Statement of Cash Flows – Supplier Finance Arrangements

The adoption of the above amendments to MFRSs did not have any significant effect on the financial statements of the Company and did not result in significant changes to the Company's existing accounting policies.

i) The Group and the Company have not adopted the following new MFRS and amendments to MFRSs that have been issued but yet to be effective:-

**MFRSs and amendment effective for annual periods beginning on or after 1 January 2025**

- Amendments to MFRS 121, The Effect of Changes in Foreign Exchange Rates – Lack of Exchangeability

**MFRSs and amendment effective for annual periods beginning on or after 1 January 2026**

- Amendments to MFRS 7, Financial Instruments: Disclosure
- Amendments to MFRS 9, Financial Instruments

Amendments that are part of Annual improvements – Volume II:-

- Amendments to MFRS 1, First time Adoption of Malaysian Financial reporting Standards
- Amendments to MFRS 7, Financial Instruments: Disclosure
- Amendments to MFRS 9, Financial Instruments
- Amendments to MFRS 10, Consolidated Financial Statements
- Amendments to MFRS 107, Statement of Cash Flows

**MFRSs and amendment effective for annual periods beginning on or after 1 January 2027**

• New MFRS to MFRS 18, Presentation and Disclosure in Financial Statements

ii) The Group and the Company plan to adopt the above applicable new MFRS and amendments to MFRSs when they become effective. A brief discussion on the above significant new MFRS and amendment to MFRSs that may be applicable to the Group and the Company are summarised below:-

**A EXPLANATORY NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR  
ENDED 30 JUNE 2025 (CONT'D)**

**MFRS 18 Presentation and Disclosure in Financial Statements**

MFRS 18 replaces MFRS 101 Presentation of Financial Statements. It retains many requirements from MFRS 101 without modification.

MFRS 18 introduces two subtotals which are to be presented in the statement of profit or loss – including “operating profit”, which has been specifically defined. Income and expenses shall be presented in five categories: operating, investing, financing, income taxes and discontinued operations.

MFRS 18 requires disclosure of explanations of the entity’s company-specific measures that are related to the statement of profit or loss, referred to as management-defined performance measures (“MPMs”). The entity is required to reconcile MPMs to a total or subtotal required by MFRS 18 or another MFRS Accounting Standards. MFRS 18 also requires other disclosures, including how each MPM is calculated, what the MPM communication about the entity’s financial performance, and any changes made to the MPMs in the year.

MFRS 18 adds new principles for aggregation and disaggregation of information. It requires the entity to classify the expenses in the “operating” category in the profit or loss by nature or function, or both. The entity that classifies operating expenses by functions are required to disclose in the notes to the financial statements, the amount of depreciation, amortisation, employee benefits, impairment losses and write-downs of inventories included in each line in the operating category. Subject to materiality, MFRS 18 requires items presented or disclosed as “other” to be labelled and/or described in as faithfully representative and precise a way as possible.

**Amendments to MFRS 121 The Effects of Changes in Foreign Exchange Rates**

Amendments to MFRS 121 respond to stakeholder feedback and concerns about diversity in practice in accounting for a lack of exchangeability between currencies.

Applying the Amendments, entities will be applying a consistent approach in determining if a currency can be exchanged into another currency. These amendments provide guidance on the spot exchange rate to use when a currency is not exchangeable into another currency and the disclosures entities need to provide to enable users of financial statements to understand the impact on the entities financial performance, financial position and cash flows as a result of a currency being not exchangeable into another currency.

**Amendments to MFRS 9 Financial Instruments and MFRS 7 Financial Instruments: Disclosures**

These narrow scope amendments to MFRS 9 clarify the classification and measurement requirements, including :-

- clarify how the contractual cash flows on financial assets with environmental, social and corporate governance and similar features should be assessed, specifically the assessment of interest focus on what an entity is being compensated for, rather than how much compensation it receives. Nonetheless, the amount of compensation the entity receives may indicate that it is being compensated for something other than basic lending risks and costs.

**A EXPLANATORY NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR  
ENDED 30 JUNE 2025 (CONT'D)**

- clarify the date on which a financial asset or a financial liability settled via electronic payment systems is derecognised. The Amendments permit an entity to derecognise a financial liability before it delivers cash on the settlement date if specified criteria are met.

Amendments to MFRS 7 introduces new disclosure requirements relating to investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features that do not relate directly to basic lending risks and costs.

Other than described above, the initial application of the new MFRS and amendments to MFRSs are not expected to have any significant impact on the financial statement of the Group and of the company.

**A2 SEASONAL OR CYCLICAL FACTORS**

The business operations of the Group are not significantly affected by any seasonal or cyclical factors.

**A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS**

There were no material unusual items affecting assets, liabilities, equity, net income, or cash flow of the Group for the financial period ended 30 June 2025.

**A4 MATERIAL CHANGES IN ESTIMATES**

There were no material changes in estimates for the financial period ended 30 June 2025.

**A5 DEBTS AND EQUITY SECURITIES**

There was no issuance, cancellation, repurchase, resale or repayments of debts or equity securities for the financial period ended 30 June 2025.

**A6 SEGMENTAL INFORMATION**

The Group's revenue by its business activities is presented as follows:

	<b>INDIVIDUAL</b>		<b>CUMULATIVE</b>	
	6 months ended 30 June		6 months ended 30 June	
	2025	2024	2025	2024
Design	3,631	1,818	3,631	1,818
Post Design	1,500	1,802	1,500	1,802
EPCC <sup>(1)</sup>	1,566	-	1,566	-
Other Support <sup>(2)</sup>	660	1,499	660	1,499
<b>Total</b>	<b>7,357</b>	<b>5,119</b>	<b>7,357</b>	<b>5,119</b>

Notes:

1- EPCC comprises works and services pertaining to engineering and/or procurement and/or construction and/or commissioning.

2- Other support mainly comprises Good Manufacturing Practice documents review, maintenance and other related engineering services.

**A EXPLANATORY NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR  
ENDED 30 JUNE 2025 (CONT'D)**

The Group's revenue by its industry is presented as follows:

	INDIVIDUAL		CUMULATIVE	
	6 months ended 30 June		6 months ended 30 June	
	2025	2024	2025	2024
	RM'000	RM'000	RM'000	RM'000
Pharmaceutical	1,965	2,957	1,965	2,957
Biotechnology	5,288	1,826	5,288	1,826
Others <sup>(1)</sup>	104	336	104	336
<b>Total</b>	<b>7,357</b>	<b>5,119</b>	<b>7,357</b>	<b>5,119</b>

Note:

1- Mainly comprised of advanced technology facilities in various industries other than pharmaceutical and biotechnology.

The Group's revenue by geographical location is presented as follows:

	INDIVIDUAL		CUMULATIVE	
	6 months ended 30 June		6 months ended 30 June	
	2025	2024	2025	2024
	RM'000	RM'000	RM'000	RM'000
Malaysia	7,073	3,300	7,073	3,300
Taiwan	274	1,819	274	1,819
United States	10	-	10	-
<b>Total</b>	<b>7,357</b>	<b>5,119</b>	<b>7,357</b>	<b>5,119</b>

The Group's revenue was generated from design, post design, EPCC and other support services from pharmaceutical and biotechnology project as well as projects for the advanced technology facilities in various industries.

For the half year ended 30 June 2025 ("1H25"), the Group experienced a notable increase in revenue, demonstrating growth in both half year period ("1H24").

- Half-Year Revenue (1H25): 7.36 million
- Increase: 43.71% compared to 1H24

This significant growth in revenue was primarily driven by the Group's operations in the local market during 1H25 and mainly attributable to higher work completion rates in ongoing biotechnology projects, as well as the successful securing of new contracts.

These newly awarded projects contributed to increased project activities across the Group's biotechnology segment, resulting in stronger topline performance.

**A7 MATERIAL EVENTS SUBSEQUENT TO THE END OF THE FINANCIAL PERIOD**

There were no material events after the date of this interim financial report.

**A EXPLANATORY NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR  
ENDED 30 JUNE 2025 (CONT'D)**

**A8 CONTINGENT ASSETS AND CONTINGENT LIABILITIES**

There are no contingent assets and contingent liabilities as at the date of this interim financial report.

**A9 CAPITAL COMMITMENTS**

There were no material capital commitments in respect of property, plant and equipment as at the date of this interim financial report.

**A10 CHANGES IN THE COMPOSITION OF THE GROUP**

There were no material changes in the composition of the Group as at the end of this interim financial report.

**B ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING  
REQUIREMENT OF BURSA MALAYSIA SECURITIES**

**B1 REVIEW OF PERFORMANCE**

**1H25 compared with 1H24**

For the half year ended 30 June 2025 (“1H25”), the Group demonstrated robust growth across key financial metrics. The revenue increase and improved profit before tax (PBT) highlight the positive trajectory driven by strong performance in the Malaysian market, particularly within biotechnology and pharmaceutical sectors.

**Revenue Performance**

- 1H25 Revenue: RM7.36 million
- 1H24 Revenue: RM5.12 million
- Increase: RM2.24 million (+43.71%)

The Group’s revenue in 1H25 increased significantly by 43.71% in the corresponding period of the previous year (“1H24”). This improvement was primarily driven by stronger contributions from local biotechnology projects, particularly due to higher project activity and work completion rates.

**Profit before Tax (PBT)**

- 1H25 PBT: RM3.73 million
- 1H24 PBT: RM2.39 million
- Increase: RM1.34 million (+56.07%)

The profit before tax (PBT) saw a significant improvement of 56.07% increasing from RM2.39 million in 1H24 to RM3.73 million in 1H25. This improvement was largely due to the higher revenue recognised during the period and improved project completion rates in the Malaysian market.

**B ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING REQUIREMENT OF BURSA MALAYSIA SECURITIES (CONT'D)**

**B2 PROSPECTS**

The Group remains cautiously optimistic about achieving a more sustainable performance in the coming periods, supported by a gradual improvement in market demand for its services. While inflationary pressures and economic uncertainties continue to pose challenges, the Group is committed to maintaining operational efficiency and delivering consistent value to its stakeholders.

Moving forward, the Group will focus on the timely execution and completion of all outstanding orders, in line with the agreed timelines with its customers. This disciplined approach to project delivery is expected to strengthen client relationships and reinforce the Group's reputation in the biotechnology sector.

As at 30 June 2025, the Group's order book stood at approximately RM64.46 million, providing earnings visibility and a solid foundation for future revenue growth.

**B3 PROFIT FORECAST, PROFIT GUARANTEE AND INTERNAL TARGETS**

The Group did not provide any profit forecast, profit guarantee or made any internal targets as at the date of this interim financial report.

**C OTHER INFORMATION**

**C1 STATUS OF CORPORATE PROPOSALS**

There were no corporate proposals announced but not completed as at the date of this interim financial report.

**C2 BORROWINGS AND DEBT SECURITIES**

As at the date of this interim financial report, there were no borrowings, and the Group has not issued any debt securities.

**C3 MATERIAL LITIGATION**

There was no pending material litigation as at the date of this interim financial report.

**C OTHER INFORMATION (CONT'D)**

**C4 TAXATION**

	UNAUDITED INDIVIDUAL		UNAUDITED CUMULATIVE	
	6 months ended		6 months ended	
	30 June	30 June	2025	2024
	2025	2024	RM'000	RM'000
<b>Current taxation</b>				
Current income tax charge	761	469	761	469
Under / (over) prior years	-	-	-	-
<b>Deferred taxation</b>	-	-	-	-
	<b>761</b>	<b>469</b>	<b>761</b>	<b>469</b>

The Group's lower tax expense in 1H24 compared to 1H25 was primarily due to the lower profit before tax recorded during the period. In contrast, the improved financial performance in 1H25 led to higher taxable income and a corresponding increase in tax expenses.

**C5 DIVIDENDS**

The directors do not recommend any final dividend for the financial year ended 31 December 2025.

No dividend has been proposed or declared during the financial period ended 30 June 2025.

**C6 EARNINGS PER SHARE**

	INDIVIDUAL		CUMULATIVE	
	6 months ended		6 months ended	
	30 June	2025	30 June	2024
	2025	2024	2025	2024
Profit attributable to owners of the Company (RM'000)	<b>2,969</b>	1,924	<b>2,969</b>	1,924
Weighted average number of shares at end of period ('000)	149,010	149,010	149,010	149,010
Earnings per ordinary share (Sen)	<b>1.99</b>	1.29	<b>1.99</b>	1.29

Diluted earnings per share is not computed as the Company did not have any convertible financial instruments as at the date of this interim financial report.